Zacks Research Has Positive Outlook for Sanofi Q1 Earnings

Sanofi (NASDAQ:SNY) – Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Sanofi in a report released on Wednesday, January 22nd. Zacks Research analyst K. Shah now anticipates that the company will earn $0.85 per share for the quarter, up from their previous forecast of $0.84. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q2 2025 earnings at $0.94 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $4.47 EPS and Q3 2026 earnings at $1.47 EPS.

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Sanofi Stock Up 1.6 %

SNY stock opened at $53.34 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market cap of $135.37 billion, a PE ratio of 27.21, a PEG ratio of 1.19 and a beta of 0.57. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a fifty day simple moving average of $48.80 and a 200 day simple moving average of $52.21.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.55 earnings per share.

Institutional Investors Weigh In On Sanofi

Hedge funds have recently modified their holdings of the business. Synergy Asset Management LLC acquired a new stake in shares of Sanofi during the 4th quarter valued at about $25,000. Northwest Investment Counselors LLC bought a new stake in Sanofi during the 3rd quarter worth approximately $29,000. Concord Wealth Partners lifted its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares in the last quarter. Fortitude Family Office LLC lifted its position in shares of Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares in the last quarter. Finally, Sunbelt Securities Inc. raised its position in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.